吡非尼酮抑制细胞焦亡减轻心肌纤维化的机制研究
Mechanism of pirfenidone inhibiting cell pyroptosis and reduceing myocardial fibrosis
何梓峰 1吕祥威 2覃泱 3赵位昆 1陈礼琴 1李月嫦 1卢钰芬1
作者信息
- 1. 541001 桂林医学院附属医院综合科医疗保健病区
- 2. 桂林医学院广西肿瘤免疫与微环境调控重点实验室
- 3. 桂林医学院附属医院研究生和毕业后教育管理部
- 折叠
摘要
目的 观察吡非尼酮对大鼠心肌纤维化的作用,并探讨其机制.方法 选取8周龄SPF级雄性SD大鼠24只,构建大鼠心房纤维化模型,随机分为假手术组、模型组、吡非尼酮低剂量组和吡非尼酮高剂量组,每组6只.假手术组和模型组分别经尾静脉注射生理盐水和异丙肾上腺素,吡非尼酮低剂量组和吡非尼酮高剂量组在注射异丙肾上腺素的基础上分别灌胃不同剂量的吡非尼酮.Masson染色检测心肌纤维化程度,免疫组织化学染色检测胶原组织Ⅰ型(Collogen-1)、核苷酸结合寡聚化结构域样受体蛋白3(NOD-like receptor thermal protein domain asso-ciated protein 3,NLRP3)炎性小体、半胱氨酸天冬氨酸蛋白酶 1(cysteinyl aspartate-specific proteinase-1,Caspase-1)的表达,Western blot检测Collogen-1和心房消皮素D(gasdermin D,GSDMD)的表达.结果 与假手术组比较,模型组心肌纤维化改变显著,Collogen-1、NLRP3、Caspase-1和GSDMD表达显著升高,差异有统计学意义(P＜0.05);与模型组比较,吡非尼酮低剂量组和吡非尼酮高剂量组心肌纤维化程度显著减轻,Collogen-1、NLRP3、Caspase-1 和 GSDMD 表达显著降低,差异有统计学意义[(8.14±1.40)％,(6.56±0.75)％vs(22.15±2.57)％,P＜0.05;0.14±0.03 vs 0.33±0.05,0.42±0.13,P＜0.05;(10.34±1.40)％,(10.33±3.40)％vs(23.22±1.99)％,P＜0.05;(15.67±0.56)％,(17.33±0.78)％vs(22.87±1.92)％,P＜0.05;0.43±0.06,0.46±0.11 vs 0.65±0.03,P＜0.05].结论 吡非尼酮通过NLRP3/Caspase-1/GSDMD信号轴抑制心肌细胞焦亡,减轻心肌纤维化.
Abstract
Objective To observe the effect of pirfenidone on myocardial fibrosis in rats and inves-tigate its underlying mechanism.Methods Twenty-four SD rats were randomly divided into sham-operation group,model group,low-and high-dose pirfenidone groups,with 6 rats in each group.Rat model of myocardial fibrosis was established by injecting isoprenaline into the tail vein,while normal saline was given to the sham operation group.Pirfenidone of 150 and 300 mg/(kg·d)were infused gastrically to the rats of low-and high-dose pirfenidone groups after modeling.Mas-son staining was used to observe the severity of myocardial fibrosis,immunohistochemical assay was employed to detect the expression of Collagen-1,NOD-like receptor thermal protein domain associated protein 3(NLRP3)inflammasome,cysteinyl aspartate-specific protease-1(Caspase-1),and Western blotting was performed to detect the protein levels of Collogen-1 and atrial desmo-plakin D(gasdermin D,GSDMD).Results The model group showed obvious myocardial fibrosis,and elevated expression of Collogen-1,NLRP3,Caspase-1 and GSDMD when compared with the sham operation group(P＜0.05).Low-and high-dose pirfenidone treatment resulted in signifi-cantly reduced myocardial fibrosis and reduced expression of Collogen-1,NLRP3,Caspase-1 and GSDMD[(8.14±1.40)％,(6.56±0.75)％vs(22.15±2.57)％,P＜0.05;0.14±0.03 vs 0.33±0.05,0.42±0.13,P＜0.05;(10.34±1.40)％,(10.33±3.40)％vs(23.22±1.99)％,P＜0.05;(15.67±0.56)％,(17.33±0.78)％vs(22.87±1.92)％,P＜0.05;0.43±0.06,0.46±0.11 vs 0.65±0.03,P＜0.05].Conclusion Pirfenidone inhibits cardiomyocyte pyroptosis and attenuates myocar-dial fibrosis through the NLRP3/Caspase-1/GSDMD signaling axis.
关键词
抗纤维化药/NLR家族,热蛋白结构域包含蛋白3/半胱氨酸天冬氨酸蛋白酶1/细胞焦亡/吡非尼酮Key words
antifibrotic agents/NLR family,pyrin domain-containing 3 protein/Caspase 1/pyropto-sis/pirfenidone引用本文复制引用
出版年
2025
NETL
NSTL
万方数据